The Influence of Cholinergic System on Rheumatoid Arthritis
Journal Title: Open Access Journal of Pharmaceutical Research - Year 2019, Vol 3, Issue 1
Abstract
Rheumatoid arthritis is one of the most prevalent immune-mediated arthritis and is categorized as a chronic, inflammatory and autoimmune disease, which mainly affects the cartilage, synovial joint, and bone, the causes of which remain unknown. There are different factors playing a role in RA pathophysiology on the molecular level, like Citrullination, Regulatory T cells, Monocytes, Macrophages, Platelet microparticles, and RASFs, which mainly induce inflammation by producing pro-inflammatory cytokines such as IL-8, IL-6, IL-1, and TNF. We have two types of cholinergic systems (CS) in our body, Neuronal CS, in which Acetylcholine (ACh) act as a neurotransmitter and NonNeuronal CS in which ACh act as a local signalling molecule for cellular proliferation and regulation of cellular function including the cells involved in RA inflammation. In light of the recent studies, the links between the CS and cells involved in RA molecular pathophysiology suggest new approaches for controlling RA, which will be discussed further. First, is the stimulation of the vagus nerve, which plays an essential role in the cholinergic anti-inflammatory pathway through its main neurotransmitter ACh resulting in downregulation of TNFα and inhibition of inflammation. The second strategy is stimulation of CAP by selective activation of α7nAChR, which is represented by different types of immune cells, such as T and B-lymphocytes, monocytes, dendritic cells, especially macrophages, and FLS through acetylcholine or its selective agonist resulting in decreased TNF production and reduced inflammation. As we discussed previously ACh is one of the necessary components for cellular proliferation especially in RASFs. Choline transporter-like proteins 1 and 2 are accountable for bringing extracellular choline inside the RASFs, which further will convert to ACh within the cell. Therefore, as the final strategy, we can induce apoptotic cell death in RASFs through preventing choline uptake by CTL1 and CTL2. Blocking of choline uptake through Choline transporter-like proteins 1 and 2, presents a novel target for RA treatment, but further in vivo studies are necessary to examine the role of these transporters as drug targets in RA.
Authors and Affiliations
Mehranfard D* and Hamurtekin E
Keywords
Related Articles
- EP ID EP745929
- DOI 10.23880/oajpr-16000170
- Views 28
- Downloads 0
Cytotoxic and Anti-Cervical Cancer Effects of the Camellia sinensis Byproducts from Various Kenyan Factories
Cervical cancer is a significant global health challenge and necessitates the search for innovative and patient-friendly therapies due to the limitations and challenges posed by conventional treatments. This study explo...
Validating the Selection Process of Healthy Control Group Based on Apparently Healthy Volunteers
Objectives: The objective of this cross sectional study is to evaluate the probability of finding healthy control subjects according to the results of multiple lab tests in multiple domains including biochemical hematolo...
No to the Herd Immunity against Novel Coronavirus (SARS-Cov-2) without Vaccination
The sheer importance of the herd’s immunity in protecting societies from the burden of contagious diseases and in providing opportunities for survival and continuity has not hidden after those societies were threatened,...
Angiotensin II Contributes to the Pathophysiology of Heart Failure
Angiotensin is a protein hormone; it is a part of the renin-angiotensin system (RAS), that causes blood vessels to become narrower, helps to maintain blood pressure and fluid balance in the body. It is the primary effect...
Formulation and Evaluation of Co-Processed Excipient
The main purpose of the current review article is to provide a comprehensive overview of the latest developments in assistive technology and the mechanisms involved in the development of those assistants. Architectural...